Why the study?
Does the presence of preoperative anti-PF4/heparin antibodies predict postoperative thromboembolic outcomes, non-thromboembolic outcomes, length of stay, and mortality in adults undergoing cardiac surgery?
Does the presence of preoperative anti-PF4/heparin antibodies predict postoperative thromboembolic outcomes, non-thromboembolic outcomes, length of stay, and mortality in adults undergoing cardiac surgery?
Pre-formed anti-PF4/heparin antibodies are common before cardiac surgery but do not predict postoperative thromboembolic complications or death.
No takes yet. Share an insight, caveat, or question.
Questions utility of preoperative anti-PF4/heparin antibody testing in cardiac surgery; extends evidence of no association with postoperative thrombosis or death.
Warkentin et al. (2011) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: